SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Intelligent Bio Solutions Inc. INBS NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Intelligent Bio Solutions Inc. (INBS) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $2.77. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: INBS trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Financials: revenue is $3M, +72.8%/yr average growth. Net income is $11M (loss), growing at -9.2%/yr. Net profit margin is -346.2% (negative). Gross margin is 40.8% (+14.8 pp trend).

Balance sheet: total debt is $281,805 against $3M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 0.77 (tight liquidity). Debt-to-assets is 3.4%. Total assets: $8M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 43/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

INBS SharesGrow Score Overview

36/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 43/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — INBS

No analyst coverage available for this stock.

INBS: +72.8%/yr revenue is, -9.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet INBS: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 0.77 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

INBS: Gross margin is 40.8% (+14.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

INBS: Net profit margin is -346.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range2.56-24.9

Volume32.93K

Avg Volume (30D)144.15K

Market Cap$1.79M

Beta (1Y)4.60

Share Statistics

EPS (TTM)-20.00

Shares Outstanding$527.36K

IPO Date2020-12-23

Employees50

CEOHarry Simeonidis

Financial Highlights & Ratios

Revenue (TTM)$3.05M

Gross Profit$1.25M

EBITDA$-9.45M

Net Income$-10.57M

Operating Income$-10.64M

Total Cash$1.02M

Total Debt$281.81K

Net Debt$-738.1K

Total Assets$8.25M

Price / Earnings (P/E)-0.1

Price / Sales (P/S)0.59

Analyst Forecast

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS36151G7097

Price Chart

INBS

Intelligent Bio Solutions Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Diagnostics & Research

2.56 52WK RANGE 24.90

People Also View

Brainstorm Cell Therapeutics Inc.

HeartSciences Inc.

Bionano Genomics, Inc.

Matinas BioPharma Holdings, Inc.

Mainz Biomed B.V.

Predictive Oncology Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message